TY - JOUR AU - Pawlotsky, J. M. AU - Feld, J. J. AU - Zeuzem, S. AU - Hoofnagle, J. H. PY - 2015 DA - 2015// TI - From non-A, non-B hepatitis to hepatitis C virus cure JO - J Hepatol VL - 62 UR - https://doi.org/10.1016/j.jhep.2015.02.006 DO - 10.1016/j.jhep.2015.02.006 ID - Pawlotsky2015 ER - TY - JOUR AU - Shi, J. AU - Li, Y. AU - Chang, W. AU - Zhang, X. AU - Wang, F. S. PY - 2017 DA - 2017// TI - Current progress in host innate and adaptive immunity against hepatitis C virus infection JO - Hepatol Int VL - 11 UR - https://doi.org/10.1007/s12072-017-9805-2 DO - 10.1007/s12072-017-9805-2 ID - Shi2017 ER - TY - JOUR AU - Perrella, A. AU - Sbreglia, C. AU - Atripaldi, L. AU - Esposito, C. AU - D’Antonio, A. AU - Perrella, O. PY - 2010 DA - 2010// TI - Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin JO - Scand J Gastroenterol VL - 45 UR - https://doi.org/10.3109/00365520903428614 DO - 10.3109/00365520903428614 ID - Perrella2010 ER - TY - JOUR AU - Ree, M. H. AU - Stelma, F. AU - Willemse, S. B. AU - Brown, A. AU - Swadling, L. AU - Valk, M. PY - 2017 DA - 2017// TI - Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing JO - Antiviral Res VL - 146 UR - https://doi.org/10.1016/j.antiviral.2017.08.016 DO - 10.1016/j.antiviral.2017.08.016 ID - Ree2017 ER - TY - JOUR AU - Hou, X. J. AU - Ye, F. AU - Li, X. Y. AU - Liu, W. T. AU - Jing, Y. Y. AU - Han, Z. P. PY - 2018 DA - 2018// TI - Immune response involved in liver damage and the activation of hepatic progenitor cells during liver tumorigenesis JO - Cell Immunol VL - 326 UR - https://doi.org/10.1016/j.cellimm.2017.08.004 DO - 10.1016/j.cellimm.2017.08.004 ID - Hou2018 ER - TY - JOUR AU - Wirth, T. C. AU - Manns, M. P. PY - 2016 DA - 2016// TI - The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma JO - Ann Oncol VL - 27 UR - https://doi.org/10.1093/annonc/mdw219 DO - 10.1093/annonc/mdw219 ID - Wirth2016 ER - TY - JOUR AU - Lemon, S. M. AU - McGivern, D. R. PY - 2012 DA - 2012// TI - Is hepatitis C virus carcinogenic? JO - Gastroenterology VL - 142 UR - https://doi.org/10.1053/j.gastro.2012.01.045 DO - 10.1053/j.gastro.2012.01.045 ID - Lemon2012 ER - TY - JOUR AU - El-Serag, H. B. AU - Kanwal, F. AU - Richardson, P. AU - Kramer, J. PY - 2016 DA - 2016// TI - Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection JO - Hepatology VL - 64 UR - https://doi.org/10.1002/hep.28535 DO - 10.1002/hep.28535 ID - El-Serag2016 ER - TY - JOUR AU - Nahon, P. AU - Layese, R. AU - Bourcier, V. AU - Cagnot, C. AU - Marcellin, P. AU - Guyader, D. PY - 2018 DA - 2018// TI - Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs JO - Gastroenterology VL - 155 UR - https://doi.org/10.1053/j.gastro.2018.07.015 DO - 10.1053/j.gastro.2018.07.015 ID - Nahon2018 ER - TY - JOUR AU - Reig, M. AU - Mariño, Z. AU - Perelló, C. AU - Iñarrairaegui, M. AU - Ribeiro, A. AU - Lens, S. PY - 2016 DA - 2016// TI - Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution JO - J Hepatol VL - 65 UR - https://doi.org/10.1016/j.jhep.2016.04.008 DO - 10.1016/j.jhep.2016.04.008 ID - Reig2016 ER - TY - JOUR AU - Rinaldi, L. AU - Francia, R. AU - Coppola, N. AU - Guerrera, B. AU - Imparato, M. AU - Monari, C. PY - 2016 DA - 2016// TI - Hepatocellular carcinoma in HCV cirrhosis after viral clearance with direct acting antiviral therapy: preliminary evidence and possible meanings JO - WCRJ VL - 3 ID - Rinaldi2016 ER - TY - JOUR AU - Conti, F. AU - Buonfiglioli, F. AU - Scuteri, A. AU - Crespi, C. AU - Bolondi, L. AU - Caraceni, P. PY - 2016 DA - 2016// TI - Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct acting antivirals JO - J Hepatol VL - 65 UR - https://doi.org/10.1016/j.jhep.2016.06.015 DO - 10.1016/j.jhep.2016.06.015 ID - Conti2016 ER - TY - JOUR AU - Kozbial, K. AU - Moser, S. AU - Schwarzer, R. AU - Laferl, H. AU - Al-Zoairy, R. AU - Stauber, R. PY - 2016 DA - 2016// TI - Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment JO - J Hepatol VL - 65 UR - https://doi.org/10.1016/j.jhep.2016.06.009 DO - 10.1016/j.jhep.2016.06.009 ID - Kozbial2016 ER - TY - JOUR AU - Romano, A. AU - Angeli, P. AU - Piovesan, S. AU - Noventa, F. AU - Anastassopoulos, G. AU - Chemello, L. PY - 2018 DA - 2018// TI - Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study JO - J Hepatol VL - 69 UR - https://doi.org/10.1016/j.jhep.2018.03.009 DO - 10.1016/j.jhep.2018.03.009 ID - Romano2018 ER - TY - JOUR AU - Calvaruso, V. AU - Cabibbo, G. AU - Cacciola, I. AU - Petta, S. AU - Madonia, S. AU - Bellia, A. PY - 2018 DA - 2018// TI - Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents JO - Gastroenterology VL - 155 UR - https://doi.org/10.1053/j.gastro.2018.04.008 DO - 10.1053/j.gastro.2018.04.008 ID - Calvaruso2018 ER - TY - JOUR PY - 2012 DA - 2012// TI - EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma JO - J Hepatol VL - 56 UR - https://doi.org/10.1016/j.jhep.2011.12.001 DO - 10.1016/j.jhep.2011.12.001 ID - ref16 ER - TY - STD TI - Associazione Italiana per lo Studio del Fegato. Documento di indirizzo dell’Associazione Italiana per lo Studio del Fegato per l’uso razionale di antivirali diretti di seconda generazione nelle categorie di pazienti affetti da epatite C cronica ammesse alla rimborsabilità in Italia. http://webaisf.org/documento-hcv-2018/. UR - http://webaisf.org/documento-hcv-2018/ ID - ref17 ER - TY - JOUR PY - 2015 DA - 2015// TI - EASL recommendations on treatment of hepatitis C 2015 JO - J Hepatol VL - 63 UR - https://doi.org/10.1016/j.jhep.2015.03.025 DO - 10.1016/j.jhep.2015.03.025 ID - ref18 ER - TY - JOUR AU - Forner, A. AU - Reig, M. E. AU - Lope, C. R. AU - Bruix, J. PY - 2010 DA - 2010// TI - Current strategy for staging and treatment: the BCLC update and future prospects JO - Semin Liver Dis VL - 30 UR - https://doi.org/10.1055/s-0030-1247133 DO - 10.1055/s-0030-1247133 ID - Forner2010 ER - TY - JOUR AU - Perrella, A. AU - Vitiello, L. AU - Atripaldi, L. AU - Conti, P. AU - Sbreglia, C. AU - Altamura, S. PY - 2006 DA - 2006// TI - Elevated CD4+/CD25+ T cell frequency and function during acute hepatitis C presage chronic evolution JO - Gut VL - 55 UR - https://doi.org/10.1136/gut.2006.099887 DO - 10.1136/gut.2006.099887 ID - Perrella2006 ER - TY - JOUR AU - Brown, R. S. PY - 2016 DA - 2016// TI - The possible association between DAA treatment for HCV infection and HCC recurrence JO - Gastroenterol Hepatol VL - 12 ID - Brown2016 ER - TY - JOUR AU - Critelli, R. AU - Milosa, F. AU - Faillaci, F. AU - Condello, R. AU - Turola, E. AU - Marzi, L. PY - 2017 DA - 2017// TI - Microenvironment inflammatory infiltrate drive growth speed and outcome of hepatocellular carcinoma: a prospective clinical study JO - Cell Death Dis VL - 8 UR - https://doi.org/10.1038/cddis.2017.395 DO - 10.1038/cddis.2017.395 ID - Critelli2017 ER - TY - JOUR AU - Perrella, A. AU - Rinaldi, L. AU - Galeota-Lanza, A. AU - Izzi, A. PY - 2018 DA - 2018// TI - DAAa and long term clinical outcome in hepatitis C: the panacea for all diseases still does not exsist JO - Am J Gastroenterol VL - 113 UR - https://doi.org/10.1038/s41395-018-0062-3 DO - 10.1038/s41395-018-0062-3 ID - Perrella2018 ER - TY - JOUR AU - Debes, J. D. AU - Tilborg, M. AU - Groothuismink, Z. M. A. AU - Hansen, B. E. AU - Schulze Zur Wiesch, J. AU - Felden, J. PY - 2018 DA - 2018// TI - Levels of cytokines in serum associate with development of hepatocellular carcinoma in patients with hcv infection treated with direct-acting antivirals JO - Gastroenterology VL - 154 UR - https://doi.org/10.1053/j.gastro.2017.10.035 DO - 10.1053/j.gastro.2017.10.035 ID - Debes2018 ER - TY - JOUR AU - Faillaci, F. AU - Marzi, L. AU - Critelli, R. AU - Milosa, F. AU - Schepis, F. AU - Turola, E. PY - 2018 DA - 2018// TI - Liver Angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular cancer after HCV direct-acting antivirals JO - Hepatology VL - 68 UR - https://doi.org/10.1002/hep.29911 DO - 10.1002/hep.29911 ID - Faillaci2018 ER - TY - JOUR AU - Grandhe, S. AU - Frenette, C. T. PY - 2017 DA - 2017// TI - Occurrence and recurrence of hepatocellular carcinoma after successful direct-acting antiviral therapy for patients with chronic hepatitis C virus infection JO - Gastroenterol Hepatol VL - 13 ID - Grandhe2017 ER - TY - JOUR AU - Kobayashi, T. AU - Nakatsuka, K. AU - Shimizu, M. AU - Tamura, H. AU - Shinya, E. AU - Atsukawa, M. PY - 2012 DA - 2012// TI - Ribavirin modulates the conversion of human CD4(+)CD25(−) T cell to CD4(+) CD25(+) FOXP3(+) T cell via suppressing interleukin-10-producing regulatory T cell JO - Immunology VL - 137 UR - https://doi.org/10.1111/imm.12005 DO - 10.1111/imm.12005 ID - Kobayashi2012 ER - TY - JOUR AU - Tan, J. AU - Ye, J. AU - Song, M. AU - Hu, Y. PY - 2018 DA - 2018// TI - Ribavirin augments doxorubicin’s efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation JO - J Biochem Mol Toxicol UR - https://doi.org/10.1002/jbt.22007 DO - 10.1002/jbt.22007 ID - Tan2018 ER - TY - JOUR AU - Farazi, P. A. AU - Pinho, R. A. PY - 2006 DA - 2006// TI - Hepatocellular carcinoma pathogenesis: from genes to environment JO - Nat Rev Cancer VL - 6 UR - https://doi.org/10.1038/nrc1934 DO - 10.1038/nrc1934 ID - Farazi2006 ER - TY - JOUR AU - Fenaux, M. AU - Lin, X. AU - Yokokawa, F. AU - Sweeney, Z. AU - Saunders, O. AU - Xie, L. PY - 2016 DA - 2016// TI - Antiviral nucleotide incorporation by recombinant human mitochondrial RNA polymerase is predictive of increased in vivo mitochondrial toxicity risk JO - Antimicrob Agents Chemother VL - 60 ID - Fenaux2016 ER - TY - JOUR AU - Jin, Z. AU - Kinkade, A. AU - Behera, I. AU - Chaudhuri, S. AU - Tucker, K. AU - Dyatkina, N. AU - Rajwanshi, V. K. PY - 2017 DA - 2017// TI - Structure–activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs JO - Antiviral Res VL - 143 UR - https://doi.org/10.1016/j.antiviral.2017.04.005 DO - 10.1016/j.antiviral.2017.04.005 ID - Jin2017 ER - TY - JOUR AU - Pawlik, T. M. AU - Delman, K. A. AU - Vauthey, J. N. AU - Nagorney, D. M. AU - Ng, I. O. AU - Ikai, I. AU - Yamaoka, Y. PY - 2005 DA - 2005// TI - Tumor predicts vascular invasion and histologic grade: implications for selection of surgical treatment for size hepatocellular carcinoma JO - Liver Transpl VL - 11 UR - https://doi.org/10.1002/lt.20472 DO - 10.1002/lt.20472 ID - Pawlik2005 ER - TY - JOUR AU - Wang, X. AU - Wang, Z. AU - Wu, L. PY - 2016 DA - 2016// TI - Combined measurement of tumor number and size helps estimate the outcome of resection of Barcelona clinic liver cancer stage B hepatocellular carcinoma JO - BMC Surg VL - 16 UR - https://doi.org/10.1186/s12893-016-0135-4 DO - 10.1186/s12893-016-0135-4 ID - Wang2016 ER -